157 related articles for article (PubMed ID: 17348259)
21. Genomic capital: public cultures and market logics of corporate biotechnology.
Rajan KS
Sci Cult (Lond); 2003 Mar; 12(1):87-121. PubMed ID: 15971369
[No Abstract] [Full Text] [Related]
22. Supporting the work of lesser geniuses: an argument for removing obstructions to human embryonic stem cell research.
Hazuka CD
Univ Miami Law Rev; 2002 Oct; 57(1):157-220. PubMed ID: 15156896
[No Abstract] [Full Text] [Related]
23. "Obvious to try": a proper patentability standard in the pharmaceutical arts?
Trask AV
Fordham Law Rev; 2008 Apr; 76(5):2625-68. PubMed ID: 18546581
[No Abstract] [Full Text] [Related]
24. Biotech patents-business as usual?
Lawrence S
Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
[No Abstract] [Full Text] [Related]
25. The making of an entrepreneurial science: biotechnology in Britain, 1975-1995.
de Chadarevian S
Isis; 2011 Dec; 102(4):601-33. PubMed ID: 22448540
[TBL] [Abstract][Full Text] [Related]
26. Property rights, genes, and common good.
Reed ED
J Relig Ethics; 2006 Mar; 34(1):41-67. PubMed ID: 17144023
[TBL] [Abstract][Full Text] [Related]
27. Drug firms lose patent rights lawsuit against South Africa's government.
Baleta A
Lancet; 2001 Apr; 357(9265):1347. PubMed ID: 11343755
[No Abstract] [Full Text] [Related]
28. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
Ghosh S
Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138
[No Abstract] [Full Text] [Related]
29. WARF's stem cell patents and tensions between public and private sector approaches to research.
Golden JM
J Law Med Ethics; 2010; 38(2):314-31. PubMed ID: 20579254
[TBL] [Abstract][Full Text] [Related]
30. A shift on "pay for delay"--reopening doors for pharmaceutical competition?
Hemphill Kraus EJ
N Engl J Med; 2012 Nov; 367(18):1681-3. PubMed ID: 23113478
[No Abstract] [Full Text] [Related]
31. [Hospital health care system (public and private) and ambulatory care system. Structure and fees].
Le Faou AL; Lioté H
Rev Prat; 1994 Apr; 44(7):973-82. PubMed ID: 7939312
[No Abstract] [Full Text] [Related]
32. Patenting basic research: myths and realities.
Kirschenbaum SR
Nat Neurosci; 2002 Nov; 5 Suppl():1025-7. PubMed ID: 12403976
[No Abstract] [Full Text] [Related]
33. Amendments to the Canadian Patent Act to address drug access: is help on the way?
Penner MD; Narayanan P
Food Drug Law J; 2005; 60(3):459-70. PubMed ID: 16304751
[No Abstract] [Full Text] [Related]
34. US policy may encourage counterfeit drugs.
Bouchie A
Nat Biotechnol; 2003 Feb; 21(2):121. PubMed ID: 12560826
[No Abstract] [Full Text] [Related]
35. [Aspects and juridical problems of the survival of public use statutes in Tuscany in the modern and contemporary eras].
Dani A
Arch Stor Ital; 1999; 157(2):285-326. PubMed ID: 19382371
[No Abstract] [Full Text] [Related]
36. The social life of genes: privacy, property and the new genetics.
Everett M
Soc Sci Med; 2003 Jan; 56(1):53-65. PubMed ID: 12435551
[TBL] [Abstract][Full Text] [Related]
37. Balancing pills and patents: intellectual property and the HIV/AIDS crisis.
Nderitu T
E Law; 2001 Sep; 8(3):E5. PubMed ID: 16903022
[No Abstract] [Full Text] [Related]
38. [3,500 years poliomyelitis and an end in sight?].
Mittenzwey W
Kinderkrankenschwester; 2004 Jan; 23(1):13-8. PubMed ID: 16137073
[No Abstract] [Full Text] [Related]
39. Proprietary rights in body parts: the relevance of Moore's case in Australia.
Mortimer D
Monash Univ Law Rev; 1993; 19(1):217-25. PubMed ID: 17333577
[No Abstract] [Full Text] [Related]
40. An unequal activism for an unequal epidemic?
Selemogo M
Dev World Bioeth; 2005 May; 5(2):153-68. PubMed ID: 15842724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
